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Abstract
Background: In the past few years, cryopreservation of ovarian tissue has become an established procedure
proposed in many centers around the world and transplantation has successfully resulted in full-term pregnancies
and deliveries in human. This prospective study aims to evaluate the feasibility of vitrifying in vitro matured
oocytes (IVM) isolated at the time of ovarian tissue cryopreservation to improve the efficiency of fertility
preservation programs.
Methods: Oocyte-cumulus complexes were retrieved from freshly collected ovarian cortex by aspirating antral
follicular fluid, and were matured in vitro for 24-48 h prior to vitrification. Oocytes were matured in an IVM
commercial medium (Copper Surgical, USA) supplemented with 75 mIU/ml FSH and 75 mIU/ml LH and vitrified
using a commercial vitrification kit (Irvine Scientific, California) in high security vitrification straws (CryoBioSystem,
France). Oocyte collection and IVM rates were evaluated according to the age, the cycle period and the amount of
tissue collected.
Results: Immature oocyte retrieval from ovarian tissue was carried out in 57 patients between 8 and 35 years of
age, undergoing ovarian tissue cryopreservation. A total of 266 oocytes were isolated, 28 of them were
degenerated, 200 were at germinal vesicle stage (GV), 35 were in metaphase I (MI) and 3 displayed a visible polar
body (MII). The number of oocytes collected was positively correlated with the amount of tissue cryopreserved (p
< 0.001) and negatively correlated with the age of the patients (p = 0.005). Oocytes were obtained regardless of
menstrual cycle period or contraception. A total maturation rate of 31% was achieved, leading to the vitrification of
at least one mature oocyte for half of the cohort.
Conclusions: The study showed that a significant number of immature oocytes can be collected from excised
ovarian tissue whatever the menstrual cycle phases and the age of the patients, even for prepubertal girls.
Background
Advances in cancer therapy have improved the long-
term survival of patients suffering from malignancies.
Thus, the number of young adults wishing to become
parents following cancer treatment has significantly
increased. However, cancer treatment often involves
a d v e r s es i d ee f f e c t s ,i n c l u d i ng loss of gonadal function
and sterility [1,2]. Chemotherapy using high doses of
alkylating agents and radiotherapy by ionizing radiation
reduces the primordial follicle reserve, which may
trigger premature ovarian failure (POF). This represents
a major concern for young patients hoping to have chil-
dren. In this context, all options for maintaining or
restoring fertility must be considered [3,4]. Oocytes and
embryos can be vitrified after ovarian stimulation or
during a natural cycle, but this strategy is not recom-
mended to all patients [5-7]. Furthermore, the number
of oocytes or embryos vitrified is often not sufficient for
more than one or two transfer attempts.
In the past few years, cryopreservation of ovarian tis-
sue has become an established procedure proposed in
many centers around the world in order to store a large
amount of primordial follicles prior to gonadotoxic
treatment [8-10]. Cryopreservation and transplantation
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any medium, provided the original work is properly cited.of ovarian tissue have successfully resulted in full-term
pregnancies and deliveries in humans [11]. One of the
major issues regarding ovarian tissue transplantation is
t h er i s ko ft r a n s m i s s i o no fc a n c e rc e l l st h a tm a yh a v e
infiltrated the ovarian tissue before the cryopreservation
procedure. In these cases, alternatives include in vitro
growth of primordial follicles but unfortunately ovarian
tissue culture system is not yet available for human
application [12,13]. Furthermore, ovarian tissue cryopre-
servation preserves the primordial and primary follicles,
but not the immature oocytes within the antral follicles
that do not survive the procedure. These oocytes could
however be recovered and subjected to in vitro matura-
tion (IVM) [14]. As reported by many authors, healthy
infants were born following IVM [15,16]. Vitrification is
now a widely applied and highly successful approach for
cryopreservation in reproductive biology, including for
the storage of human oocytes [17-19]. Recently, studies
reported almost 100% morphological survival rate after
vitrification of in vivo aspirated mature oocytes. The
authors also reported in vitro embryo development,
implantation and pregnancy rates comparable to those
achieved with fresh oocytes [20-22].
The present study assessed the efficiency of IVM and
vitrification procedures of the immature oocytes in
excised ovarian tissue according to the age of the
patients and their menstrual cycles.
Methods
The procedure was approved by the local ethical com-
mittee. It was explained to patients and informed con-
sent was obtained.
Patients
From November 2008 to December 2010, 57 patients
between 8 and 35 years of age (mean age 26), referred
to Erasme Hospital for ovarian tissue cryopreservation
as part of a fertility preservation program, underwent a
combined oocyte vitrification procedure after counsel-
ing. Seven patients underwent oophorectomy, while the
others had ovarian cortex biopsies. The indications for
ovarian tissue cryopreservation were breast cancers (n =
26), hematological diseases (n = 20), gynecological dis-
eases (n = 7), solid malignancies (n = 2) and auto-
immune diseases (n = 2). The inclusion criteria for the
cryopreservation of ovarian tissue were previously
described [8]. Patients treated with chemotherapy before
the ovarian tissue cryopreservation procedure were
excluded from this study [23].
Oocyte collection and in vitro maturation
The surgical collection and freezing procedures for the
ovarian tissue were described elsewhere [8]. Large biop-
sies of the ovarian cortex (approximately total of half
ovary) were removed by laparoscopy except for patients
treated with high-dose alkylating agents and autologous
stem-cell transplantation, who underwent a unilateral
oophorectomy considering their high risk of premature
ovarian failure. Oophorectomy was also required in
some ovarian diseases, but only a part of the cortex was
designated for cryopreserva t i o ni nt h e s ep a t i e n t s .T h e
ovarian cortex was transported to the IVF laboratory in
Leibovitz L-15 medium (Life Technologies, Merelbeke,
Belgium) at 4°C within the hour. At arrival, oocyte-
cumulus complexes (OCCs) were recovered by aspirat-
ing all visible antral follicles using 18-gauge syringe nee-
dles. The aspirated follicular fluid was poured directly
into a Petri dish and examined for OCCs under a
stereomicroscope. The ovarian specimens were trans-
ferred into a new dish containing the same medium and
carefully dissected in order to obtain small slices of
ovarian cortex (0.5-1 cm diameter, 1-2 mm thickness).
After dissection of the ovarian tissue, the discarded
material was filtered through a cell strainer (Falcon, Cell
Strainer 352350, 70 μm Nylon) in a Petri dish (Falcon,
Petri dishes 3004, 60 × 15 mm) containing 3-5 ml of
IVM Washing Medium (Sage, IVM Kit media) at 37°C
o naw a r ms t a g eo rp l a t et op r e v e n tt h eO C C sf r o m
drying in the strainer. After filtering, the collected mate-
rial was rinsed with pre-warmed IVM Washing Medium
and transferred into a Petri dish to search a second time
for OCCs under a stereomicroscope. All retrieved OCCs
were scored and classified according to the oocyte
nuclear stage as germinal vesicle (GV), germinal vesicle
breakdown (metaphase I-MI) or metaphase II when a
first polar body is visible in the perivitelline space (MII).
OCCs with unvisualized oocyte nuclear status due to
the compact cumulus cells surrounded it were consid-
ered as GV. OCCs were washed at least three times in
pre-warmed IVM Washing Medium and transferred
into an Organ Tissue Culture Dish (Nunc, 176742, 4
wells dishes) containing 0.5 ml IVM Maturation Med-
ium (Sage, IVM Kit media) supplemented with 75 mIU/
ml FSH and 75 mIU/ml LH and incubated at 37°C in a
5% CO2 humidified atmosphere. The IVM Maturation
Medium was prepared for equilibration at least two
hours before the immature oocyte retrieval. The imma-
ture OCCs were cultured in the IVM Maturation Med-
ium for 24 to 48 hours.
Vitrification
Twenty-four hours after IVM, all the OCCs were
denuded using a 130 micron finely drawn pipette fol-
l o w i n go n em i n u t eo fe x p o s u r et o8 0I U / m lh y a l u r o n i -
dase solution (Sigma Aldrich SrL, UK.). The mature
oocytes (MII) were then subjected to vitrification follow-
ing a standard protocol (Irvine, Vitrification Kit media)
using aseptic devices (CryoBiosystem, VHS Kit). The
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IVM Maturation Medium for an additional 24 hours.
Forty-eight hours after IVM, the remaining oocytes
that reached MII were vitrified.
Statistical analysis
Statistical analyses were performed using the Chi-
squared, t-Test and Non parametric Mann-Whitney
Test as appropriate. Linear correlations between two
v a r i a b l e sw e r ea n a l y z e db yc a l c u l a t i o no ft h er - v a l u e s
(Pearson’s moment-correlation coefficient); the signifi-
cance (two-tailed probability values) of r coefficients
were calculated on the basis of the correlation values.
Values of p < 0.05 indicated statistical significance.
Results
From the cohort of 57 patients, 19% were using contra-
ception treatment (mean age 23.1, range 17-33), 33%
were in the follicular phase of a spontaneous menstrual
cycle (mean age 26.3, range 14-35), 28% were in the
luteal phase (mean age 27.9, range 22-34), 7% were pre-
pubertal (mean age 9.2, range 8-13), 9% were in post-
partum amenorrhea (mean age 31, range 23-35) and for
2 patients, information was unavailable (Table 1). A
total of 266 oocytes were retrieved, 28 of them were
degenerated (10.5%). In the 238 healthy oocytes, 200
were at germinal vesicle stage (GV), 35 were in meta-
phase I (MI) and 3 displayed a visible polar body (MII).
In 15/57 patients, no oocytes were found (26.3%). The
number of oocytes collected was positively correlated
with the amount of tissue cryopreserved (p < 0.001) and
negatively correlated with the age of the patients (p =
0.005). As shown in Table 1 immature oocytes were
retrieved regardless of the menstrual cycle phases. The
mean number of oocytes retrieved was however higher
in prepubertal compared to post-pubertal patients
(Table 1). For post-pubertal patients, no difference in
the number of oocyte collected was observed between
patients less or over 30 year-old (Table 2).
The total IVM rate was 31% (20% after 24 h IVM and
11% after 48 h IVM). For patients with natural cycles,
the IVM rate was similar whatever the phase of the
menstrual cycle. No significant difference was observed
in the maturation rate between patients using contra-
ception or those in a natural cycle as well as between
pre- and post-pubertal patients. For 3 patients, in vitro
matured oocytes (4, 1 and 5 respectively) were fertilized
by ICSI and the embryos obtained (1, 1 and 3 respec-
tively) were vitrified.
In more than half of the patients (54%), at least one
mature oocyte was vitrified after 24 or 48 hours. In 3/4
prepubertal patients, MII were vitrified, suggesting that
the procedure is suitable and more efficient for prepu-
bertal patients where antral follicles are present.
Discussion
The cryopreservation of ovarian tissue allows the preser-
vation of a large number of primary follicles before
gonadotoxic treatment. However, growing immature
oocytes from antral follicles are lost during the proce-
dure. Vitrification of in vitro matured oocytes collected
after punction of these antral follicles in the excised
ovarian tissue before cryopreservation has been pro-
posed as an additional technique to preserve fertility.
This procedure may increase fertility restoration poten-
tial and may also be an important alternative whereby
neoplasic cells can potentiallyi n f i l t r a t eo v a r i a nt i s s u e ,
leading to a risk of disease recurrence after transplanta-
tion, as in some hematological diseases or in advanced
breast cancer [24,25].
This study shows that isolated immature oocytes from
antral follicles can be retrieved from the ovarian tissue
biopsy, consequently in vitro matured and vitrified dur-
ing any phase of the menstrual cycle and whether or
Table 1 Outcome of immature oocyte retrieved from ovarian cortex according to the menstrual cycle characteristic
Characteristic of the
patient’s menstrual cycle
Patients
n
Mean
age ±
SEM
Mean fragments of
ovarian tissue (range)
Oocytes
retrieved
n (range)
Mean
oocytes
retrieved
/fragment
Mean
oocytes
retrieved
/patients
Stage at
collection (%)
IVM
rate
GV MI MII
OC 11 23.1 ± 1.3 20.1 (10-29) 38 (0-9) 0.17 ± 0.07
a 3.4 ± 1.06
a 71% 29% 0% 42.1%
Natural cycle FP 19 26.3 ± 1.5 21.6 (7-32) 69 (0-15) 0.17 ± 0.06
a 3.6 ± 1.09
a 80% 19% 1% 27.9%
Natural cycle LP 16 27.9 ± 1.1 18.1 (12-26) 44 (0-13) 0.15 ± 0.05
a 2.8 ± 0.83
a 84% 14% 2% 39.5%
Post-partum 5 31 ± 2.2 26.3 (16-36) 33 (1-12) 0.23 ± 0.12
a 6.6 ± 1.86 91% 6% 3% 28.1%
Unknown 2 29.5 ± 0.5 20-32 8 (0-8) 0.15 ± 0.26 4 ± 4 100% 0% 0% 12.5%
Prepubertal 4 9.2 ± 1.4 31.7 (17-40) 46 (2-22) 0.36 ± 0.28
b 11.5 ± 4.27
b 93% 7% 0% 23.9%
Total 57 26 ± 0.9 21.8 (7-40) 238 (0-22) 0.19 4 84% 14.7% 1.3% 31%
GV = germinal vesicle; MI = metaphase I; MII = metaphase II; OC = oral contraception; FP = follicular phase; LP = luteal phase; IVM = in vitro maturation; n =
number;
a vs b within the same column, p < 0.05
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of oocytes collected is correlated with the number of
cryopreserved fragments and the age of the patients.
However, the IVM rate is similar whatever the phase of
the menstrual cycles or the age of patient. These results
suggest that the procedure can be proposed to any
patient undergoing ovarian tissue cryopreservation, with
the exception of those who have already begun
chemotherapy.
The procedure described above, allows the vitrification
of matured oocytes in approximately half of the patients
although the total IVM rate was lower than the one pre-
viously described using oocytes directly retrieved in vivo.
In a recent study, a mean oocyte maturation rate of
around 70% was achieved following direct oocyte retrie-
val after hCG injection during a natural cycle [26]. The
recent success of in vitro oocyte maturation strategies
has been attributed to the improvement of the culture
media composition [27-29]. In immature oocytes
retrieved from ovarian tissue, the delay in relation to
transport and oocyte collection is a major issue and may
decrease the efficiency of IVM. Revel et al. [30] first
described oocyte collection during the cryopreservation
of ovarian tissue in 9 patients, amongst whom 3
attempted IVM. In these patients, 5 of 8 MI oocytes
were matured in vitro. Other studies including small
number of patients or case reports have been described,
confirming the feasibility of the procedure [31-33]. In
o u rc o h o r t ,t h eI V Mr a t ew a sh i g h l yv a r i a b l ef r o mo n e
patient to other ranging from 0 to 100%, with an aver-
age of 31%. This result is consistent with the only pre-
vious study using a large cohort of 19 patients under 20
years of age, showing that 34% of immature oocytes col-
lected from ovarian tissue before cryopreservation are
competent to resume meiosis in vitro [34].
Healthy infants have been born following IVM
[35-37], and oocyte cryopreservation by vitrification
seems a promising technique that appears to be more
effective than the conventional slow-freezing method for
mature oocytes vitrified shortly after collection [38-40].
In this context, vitrification results in high survival rates
of 89-100% and many successful live births worldwide
[41-43]. Given these recent successes, although the effi-
ciency of this combined procedure has to be determined
by testing the potential for the implantation of embryos
derived from these in vitro matured and vitrified
oocytes, it is reasonable to suggest this innovative and
non-invasive alternative, under institutional review
board supervision. Furthermore, if a male partner is pre-
sent, the in vitro matured oocytes may be fertilized
using the in vitro fertilization (IVF) technique, and the
resulting embryos may be cryopreserved. For 3 patients,
in vitro matured oocytes were fertilized and the embryos
obtained were vitrified. Theses cases are reassuring
regarding the oocyte quality as it suggests that these
oocytes are competent to be fertilized.
Conclusion
This study shows that the combination of ovarian tissue
cryopreservation and immature oocyte retrieval is feasible
whatever the phase of menstrual cycle, the use of oral
contraception or the age of the patient. Approximately
half of these patients should benefit from this combined
procedure, and improvement of the IVM rate may better
increase the efficiency of the procedure in the future.
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Table 2 Outcome of immature oocyte retrieved from ovarian tissue of post-pubertal patients according to the age
Age Patients
n
Mean age
± SEM
Mean fragments of ovarian
tissue (range)
Oocytes
retrieved
n (range)
Mean oocytes
retrieved
/fragment
Mean oocytes
retrieved
/patients
Stage at
collection (%)
IVM
rate
GV MI MII
<3 0
years
30 23.6 ± 0.71 21 (7-32) 99 (0-10) 0.16 ± 0.02 3.3 ± 0.53 83.8% 15.1% 1% 31.3%
≥ 30
years
23 32 ± 0.40 20.9 (11-36) 93 (0-15) 0.18 ± 0.04 4 ± 1.04 79.6% 18.3% 2.1% 30.3%
GV = germinal vesicle; MI = metaphase I; MII = metaphase II; OC = oral contraception; FP = follicular phase; LP = luteal phase; IVM = in vitro maturation; n =
number
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